Skip to main content

Advertisement

Table 5 Logistic regression analysis for verifying the risk factors for the early termination of nintedanib

From: Negative impact of anorexia and weight loss during prior pirfenidone administration on subsequent nintedanib treatment in patients with idiopathic pulmonary fibrosis

  Univariate Multivariate
Odds ratio 95% CI p value Odds ratio 95% CI p value
Age 1.02 0.885–1.18 0.751    
Gender (male/female) 1.18 0.197–7.08 0.855    
Never smoker (%) 0.857 0.104–7.04 0.886    
Body weight (kg) 0.931 0.861–1.01 0.0702    
Body mass index 0.704 0.519–0.955 0.0239 0.487 0.280–0.849 0.0111
Body surface area (DuBois, m2) 0.0418 0.000541–3.22 0.152    
Creatinine (mg/dL) 1.07 0.0280–40.7 0.972    
Krebs von den Lungen-6 (U/mL) 1 0.999–1.00 0.348    
Surfactant protein D (ng/dL) 0.995 0.989–1.00 0.08 0.997 0.990–1.00 0.315
Forced vital capacity (L) 0.561 0.150–2.1 0.391    
% Forced vital capacity (%) 0.967 0.918–1.02 0.213    
% DLco (%) 1.01 0.9580–1.06 0.739    
Administration period of Pirfenidone 1 0.999–1.00 0.329    
Time from pirfenidone discontinuation to nintedanib initiation 1.01 0.994–1.02 0.355    
Discontinued pirfenidone due to FVC decline 0.333 0.0751–1.48 0.148    
Anorexia during the period of pirfenidone 1.65 0.370–7.37 0.512    
Weight loss during the period of pirfenidone 2.93 0.657–13.1 0.159    
Weight loss with grade ≥ 2 during the period of pirfenidone 7.8 0.804–75.6 0.0764 3.29 0.184–58.8 0.418
  1. Univariate analysis showed that the association between low body mass index and the early termination of nintedanib was statistically significant (p = 0.0239). In addition, the association between weight loss with a CTCAE grade of ≥2 during the pirfenidone administration period and the early termination of nintedanib was also marginally significant (p = 0.0764). A multivariate logistic regression analysis using backward stepwise selection showed that the association between BMI and the early termination of nintedanib was statistically significant (p = 0.0111)
  2. Abbreviation: DLCO diffusing capacity for lung carbon monoxide